Although there are some exciting success stories such as the vastly improved survival with imatinib and chronic myelogenous leukemia (CML) or the increased efficacy of Herceptin treatment for women with Her2-positive breast cancer, most of this new generation of targeted treatments promise, at most, only a partial respite from the disease. This evidence concerns the gene ERBB2 and chronic myelogenous leukemia, BCR-ABL1 positive.